

BC Cancer ST Program Updates for March 2023

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- **For PowerPlans that are versioned:** If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version.
 - **Do not** use the Copy Forward functionality to ensure that the updates apply.



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below:

PowerPlan: GUTIP, SAAVIME3, SCMESNA for SAIME or SAAVIME3, SAIME

Cycles/PowerPlans: ONCP GU GUTIP, ONCP SA SAAVIME3, ONCP SC SCMESNA for SAIME or SAAVIME3, ONCP SA SAIME (inpatient)

Changes:

- The ranitidine order has been replaced with an optional famotidine 20mg PO BID order.

ONCP GU GUTIP (Inpatient) - Cycle 1, Chemotherapy Related Orders (Future Pending)		
Post-Chemo Antiemetics		
<input checked="" type="checkbox"/>	ondansetron	8 mg, PO, q12h, order duration: 9 d Days 2 to 6
<input checked="" type="checkbox"/>	dexamethasone	4 mg, PO, BID, order duration: 9 d Days 2 to 6
<input checked="" type="checkbox"/>	aprepitant	80 mg, PO, q24h, order duration: 2 Day 3 and 4
Supportive Care Medications		
<input type="checkbox"/>	famotidine	20 mg, PO, BID, drug form: tab
PRN Medications		
<input checked="" type="checkbox"/>	+1 day ondansetron	8 mg, IV, q12h, PRN other (see com If patient does not tolerate PO. Day

Versioning: Yes

Jira: CST-203158

PowerPlan: LYHDMRTEM

Cycles/PowerPlans: All PowerPlans

Changes:

- Ranitidine has been replaced with famotidine in the yellow banner "write orders for dexamethasone and ranitidine for inpatient use, if applicable".

ONCP LY LYHDMRTEM (Inpatient) Cycles 1 to 4 - Cycle 1, Chemotherapy Related Orders (Future Pending)		
Supportive Care Medications		
Leucovorin dose may need to be adjusted upwards depending on methotrexate level.		
<input checked="" type="checkbox"/>	leucovorin (leucovorin - oncology)	
Write orders for dexamethasone and famotidine for inpatient use, if applicable		
If patient is on dexamethasone, start co-trimoxazole (800mg-160mg) 1 tablet PO three beginning methotrexate and resume when methotrexate level is less than 0.1 micromol		
PRN Medications		

Versioning: Yes

Jira: CST-203154

PowerPlan: UGIPRRT

Cycles/PowerPlans: ONCP GI UGIPRRT

Changes:

Next Cycle Labs Phase:

- Removed the following orders: urea, uric acid, alkaline phosphatase, GGT, LDH, TSH, random glucose, T3, T4.

Nuclear Medicine Phase:

Premedications:

- Changed default to ondansetron IV.

ONCP GI UGIPRRT - Cycle 1, Nuclear Medicine (Day 1) (Future Pending) *Es

	Component
Pre-Medications	
	⚠ Patient to take own supply of pre-medications. RN/Pharmacist to confirm
<input type="checkbox"/>	⊞ ⚠ ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to treatment. Day 1
<input checked="" type="checkbox"/>	⊞ ⚠ ondansetron 8 mg, IV, once oncology, drug form: inj Between 30 and 60 minutes prior to treatment. Day 1
	⚠ If hypersensitivity reactions have occurred, see protocol or BC Cancer hypersensitivity guidelines (SCDRUGRX) for additional pre-medications

Treatment

- The second octreotide order line now defaults to 200mcg order sentence.

	Treatment Regimen
<input checked="" type="checkbox"/>	⚠ Zero Time
<input checked="" type="checkbox"/>	⚠ 2.5% Lys-Arg Amino Acid 1,000 mL, IV, once oncology, administer over: 4 hour, drug f... Day 1 ⚠ For symptoms of carcinoid flare such as diarrhea, flushing, hypotension, bronchoconstriction or unstable ...
<input checked="" type="checkbox"/>	⚠ octreotide ▼ 100 mcg, subcutaneous, q5min, PRN other (see comme... For carcinoid flare. May repeat x 1. Call MD after 1st dose
<input checked="" type="checkbox"/>	⚠ octreotide ▼ 200 mcg, subcutaneous, q1h oncology, PRN other (see c... For carcinoid flare. Following initial octreotide dose
	⚠ Patient must be kept in radiation isolation for a period of 4-5 hours following administration of Lutetium 177-Lu-Dotatate (LUTATHERA) and discharge dose rate must be less than 25 microSv/hr at 1 meter distance

Versioning: Yes

Jira: CST-203013

PowerPlan: LYRICE

Cycles/PowerPlans: ONCP LY LYRICE

Changes:

- Added 125mg aprepitant and olanzapine (2.5mg, 5mg, 10mg options) orders.
- Added blue note "If aprepitant ordered, ensure patient takes aprepitant 80 mg PO daily for Days 2 and 3".

Pre-Medications	
	Patient to take own supply of pre-medications. RN/Pharmacist to confirm
<input checked="" type="checkbox"/>	ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to treatment. Days 1 to 3
<input checked="" type="checkbox"/>	dexamethasone 12 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to treatment. Days 1 to 3
<input type="checkbox"/>	aprepitant 125 mg, PO, once oncology, drug form: cap, Use Patient Su... Between 30 and 60 minutes prior to treatment. Day 1
	If aprepitant ordered, ensure patient takes aprepitant 80 mg PO daily for Days 2 and 3
<input type="checkbox"/>	OLANZapine ▼ Select an order sentence
<input type="checkbox"/>	diphenhydrAMINE 50 mg, IV, once oncology, drug form: inj

Versioning: Yes

Jira: CST-203000

PowerPlan: GUBEP, GUEP

Cycles/PowerPlans: ONCP GU GUBEP, ONCP GU GUEP

Changes:

- Updated order comment of optional hydrocortisone and diphenhydramine to "... prior to etoposide or etoposide phosphate (ETOPOPHOS)".

<input checked="" type="checkbox"/>	hydrocortisone 100 mg, IV, once oncology, drug form: inj, first dose: ... Between 30 and 60 minutes prior to etoposide or etoposi...	+30 min Planned
<input type="checkbox"/>	diphenhydrAMINE 50 mg, IV, once oncology, drug form: inj Between 30 and 60 minutes prior to etoposide or etoposide	+30 min

Details for hydrocortisone

Details Order Comments

Order comments

Between 30 and 60 minutes prior to etoposide or etoposide phosphate (ETOPOPHOS). Days 1 to 5

- Added yellow banner above etop phos order "if hypersensitivity to etoposide: omit etoposide."
- Added yellow banner "Approval from the Health Canada Special Access Program must be obtained to give etoposide phosphate (ETOPOPHOS) for each patient."
- Added unchecked etoposide phosphate order.
- Applied linking rule between etoposide and etoposide phosphate to only choose one.
- Updated offset of etoposide phosphate (ETOPOPHOS) to 30 minutes.

<input checked="" type="checkbox"/>	etoposide (etoposide - oncology) 100 mg/m2, IV, once oncology, administer over: 45 minute, ... Use non-DEHP tubing with 0.2 micron in-line filter. May ad...	+30 min Planned
<input checked="" type="checkbox"/>	bleomycin (bleomycin - oncology) 30 unit, IV, once oncology, administer over: 10 minute, drug ... Days 1, 8, 15	+90 min Planned
<input type="checkbox"/>	If hypersensitivity to etoposide: omit etoposide etoposide phosphate (etoposide phosphate (ETOPOPH... 100 mg/m2, IV, once oncology, administer over: 45 minute, ... May administer over 45 to 90 minutes. Days 1 to 5	+30 min
	Approval from the Health Canada Special Access Program must be obtained to give etoposide phosphate (ETOPOPHOS) for each patient	
	Post-Hydration	

Versioning: Yes

Jira: CST-202932

PowerPlan: LYGDP, LYGDPR

Cycles/PowerPlans: All powerplans

Changes:

Carboplatin option plans:

- Added aprepitant, netupitant-palonosetron orders and associated notes "Reminder to deselect ondansetron if giving netupitant-palonosetron".
- Added olanzapine (2.5mg, 5mg, 10mg options) for Day 1 only.

ONCP LY LYGDP CARBOplatin Option - Cycle 1, Chemotherapy (Day 1, 8) (Future Pending) *Est.		
	Component	Day 1 Future Pending *Est. 24-Feb-2023 08:...
<input type="checkbox"/>	aprepitant 125 mg, PO, once oncology, drug form: cap, Use Patient Su... Between 30 and 60 minutes prior to treatment. Day 1	-30 min
	Reminder to deselect ondansetron if giving netupitant-palonosetron	
<input type="checkbox"/>	netupitant-palonosetron (netupitant-palonosetron 300 ... 1 cap, PO, once oncology, drug form: cap, Use Patient Supply Between 30 and 60 minutes prior to treatment. Day 1	-30 min
<input type="checkbox"/>	OLANZapine ▼ Select an order sentence	-30 min
<input checked="" type="checkbox"/>	prochlorperazine	

Cisplatin option plans:

- Added olanzapine (2.5mg, 5mg, 10mg options) per PPO for Day 1.

ONCP LY LYGDPR CISplatin Option - Cycle 1, Chemotherapy (Day 1, 8) (Future Pending) *Est. 24-Feb-2023 08:...		
	Component	Day 1 Future Pending *Est. 24-Feb-2023 08:...
<input type="checkbox"/>	OLANZapine ▼ Select an order sentence	-30 min
<input checked="" type="checkbox"/>	prochlorperazine 10 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 to 60 minutes prior to treatment. Day 8	

Cisplatin split dosing option plans:

Chemotherapy phase (premedications):

- Added olanzapine (2.5mg, 5mg, 10mg options) for both DOT.

ONCP LY LYGDPR CISplatin Split Dosing Option - Cycle 1, Chemotherapy (Day 1, 8) (Future Pending)		
		Day 1
		Component
<input type="checkbox"/>	OLANzapine	Future Pending
	▼ Select an order sentence	*Est. 24-Feb-2023 08:...
	Pre-Hydration	Actions ▼
		-30 min

Versioning: Yes

Jira: CST-202931

PowerPlan: GUSCPE, GUSCPERT

Cycles/PowerPlans: All powerplans

Changes:

- Added 125 mg aprepitant and olanzapine (2.5mg, 5mg, 10mg options) orders.
- Added blue note "If aprepitant ordered, ensure patient takes aprepitant 80 mg PO daily for Days 2 and 3".

ONCP GU GUSCPE CISplatin Option - Cycle 1, Chemotherapy (Day 1 to 3) (Future Pending) *Est. 24		
		Day 1
		Component
<input type="checkbox"/>	aprepitant 125 mg, PO, once oncology, drug form: cap, Use Patient Su... Between 30 and 60 minutes prior to treatment. Day 1	Future Pending
	If aprepitant ordered, ensure patient takes aprepitant 80 mg PO daily for Days 2 and 3	*Est. 24-Feb-2023 08:...
<input type="checkbox"/>	OLANzapine	Actions ▼
	▼ Select an order sentence	-30 min

Versioning: Yes

Jira: CST-202924

PowerPlan: GUSCARB

Cycles/PowerPlans: ONCP GU GUSCARB

Changes:

Chemotherapy Phase (Premedications)

- Added 125mg aprepitant, netupitant-palonosetron, olanzapine (2.5mg, 5mg, 10mg options).
- Added yellow note "Reminder to deselect ondansetron if giving netupitant-palonosetron".
- Update ondansetron order comments to include "Do not give if patient given netupitant-palonosetron".

ONCP GU GUSCARB - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est.

		Component
		Pre-Medications
		Patient to take own supply of pre-medications. RN/Pharmacist to confirm
<input checked="" type="checkbox"/>		dexamethasone 8 mg, PO, once oncology, drug form: tab, Use Patient S... Between 30 and 60 minutes prior to treatment. Day 1
<input checked="" type="checkbox"/>		ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Do not give if patient given netupitant-palonosetron. Betwe...
<input type="checkbox"/>		aprepitant 125 mg, PO, once oncology, drug form: cap, Use Patient Su... Between 30 and 60 minutes prior to CARBOplatin. Day 1
		Reminder to deselect ondansetron if giving netupitant-palonosetron
<input type="checkbox"/>		netupitant-palonosetron (netupitant-palonosetron 300 ... 1 cap, PO, once oncology, drug form: cap, Use Patient Supply Between 30 and 60 minutes prior to CARBOplatin. Day 1
<input type="checkbox"/>		OLANZapine Select an order sentence

Versioning: Yes

Jira: CST-202919

PowerPlan: GUVIP2

Cycles/PowerPlans: ONCP GU GUVIP2

Changes:

- Added yellow banner above etop phos order “if hypersensitivity to etoposide: omit etoposide”.
- Added yellow banner “Approval from the Health Canada Special Access Program must be obtained to give etoposide phosphate (ETOPOPHOS) for each patient.”
- Added unchecked etoposide phosphate order.
- Applied linking rule between etoposide and etoposide phosphate to only choose one.
- Updated offset of etoposide phosphase (ETOPOPHOS) to match etoposide (0 minutes).

ONCP GU GUVIP2 (Inpatient) - Cycle 1, Chemotherapy (Day 1 to 5) (Future Pending) *Est. 23-Feb-

		Day 1
		Future Pending
		*Est. 23-Feb-2023 15:...
		Actions ▾
Treatment Regimen		
<input checked="" type="checkbox"/>	Zero Time	0 hr Planned
<input checked="" type="checkbox"/>	etoposide (etoposide - oncology) 75 mg/m2, IV, once oncology, administer over: 60 minute, d... Use non-DEHP tubing with 0.2 micron in-line filter. Hour 0 t...	0 min Planned
	If hypersensitivity to etoposide: omit etoposide	
<input type="checkbox"/>	etoposide phosphate (etoposide phosphate (ETOPOPH...) 75 mg/m2, IV, once oncology, administer over: 60 minute, d... Hour 0 to 1. Days 1 to 5	0 min
	Approval from the Health Canada Special Access Program must be obtained to give etoposide phosphate (ETOPOPHOS) for each patient	

Versioning: Yes

Jira: CST-202901

PowerPlan: GIAAVCT

Cycles/PowerPlans: ONCP GI GIAAVCT

Changes:

- Removed mandatory Cr on day 8 and 15.

Versioning: Yes

Jira: CST-202893

PowerPlan: All trastuzumab-containing PowerPlans (list below)

Cycles/PowerPlans: All trastuzumab-containing PowerPlans (list below)

Changes:

- Immediately after the current trastuzumab - oncology order, added a yellow note "Choose 8 mg/kg for trastuzumab re-loading, and notify scheduling to adjust appointment length:"
- Added an additional, unchecked trastuzumab - oncology order with the same Time Zero offset and Treatment Schedule as the existing trastuzumab – oncology order with the following order sentence:
 - o 8 mg/kg, IV, once oncology, administer over: 90 minute, drug form: bag, Order Comment: Observe for 60 minutes post infusion. Day 1 .
- Linked the current and new trastuzumab – oncology orders so only 1 can be chosen.

Treatment Regimen		
<input checked="" type="checkbox"/>	Zero Time	0 hr Planned
<input checked="" type="checkbox"/>	trastuzumab (trastuzumab - oncology) 6 mg/kg, IV, once oncology, administer over: 60 minute, dru... Observe for 30 minutes post infusion. Day 1	0 min Planned
	Choose 8 mg/kg for trastuzumab re-loading, and notify scheduling to adjust appointment length:	
<input type="checkbox"/>	trastuzumab (trastuzumab - oncology) 8 mg/kg, IV, once oncology, administer over: 90 minute, dru... Observe for 60 minutes post infusion. Day 1	0 min

These changes have been made to the following plans:

ONCP BR BRAJACTT Cycle 6
 ONCP BR BRAJACTT Cycles 7 and 8
 ONCP BR BRAJACTTG Cycle 6
 ONCP BR BRAJACTTG Cycles 7 to 8
 ONCP BR BRAJDCARBT Cycle 1
 ONCP BR BRAJDCARBT Cycle 2
 ONCP BR BRAJDCARBT Cycles 3+
 ONCP BR BRAJFECDT Cycle 5
 ONCP BR BRAJFECDT Cycle 6
 ONCP BR BRAJTDC Cycle 2
 ONCP BR BRAJTDC Cycles 3 and 4
 ONCP BR BRAJTR Cycle 2
 ONCP BR BRAJTR Cycles 3+
 ONCP BR BRAJTTW Cycle 2
 ONCP BR BRAJTTW Cycles 3 to 4
 ONCP BR BRAVPTRAD Cycle 2
 ONCP BR BRAVPTRAD Cycle 9

ONCP BR BRAVPTRAD Cycles 3 to 8
 ONCP BR BRAVPTRAD Maintenance 21 Day Cycle Option Cycles 10+
 ONCP BR BRAVPTRAD Maintenance 28 Day Cycle Option Cycles 10+
 ONCP BR BRAVPTRAT Cycle 2
 ONCP BR BRAVPTRAT Cycle 9
 ONCP BR BRAVPTRAT Cycles 3 to 8
 ONCP BR BRAVPTRAT Maintenance 21 Day Cycle Option Cycles 10+
 ONCP BR BRAVPTRAT Maintenance 28 Day Cycle Option Cycles 10+
 ONCP BR BRAVTCAP
 ONCP BR BRAVTR 21 Day Cycle Option Cycle 2
 ONCP BR BRAVTR 21 Day Cycle Option Cycles 3+
 ONCP BR BRAVTR 28 Day Cycle Option Cycle 2
 ONCP BR BRAVTR 28 Day Cycle Option Cycles 3+
 ONCP BR BRLAACDT Cycle 6
 ONCP BR BRLAACDT Cycles 7 and 8
 ONCP GI GIGAVCCT Cycle 2
 ONCP GI GIGAVCCT Cycles 3+
 ONCP GI GIGAVCFT Cycle 2
 ONCP GI GIGAVCFT Cycles 3+
 ONCP GI GIGAVCOXT Cycle 2
 ONCP GI GIGAVCOXT Cycles 3+
 ONCP GI GIGAVFFOXT Cycle 1
 ONCP GI GIGAVFFOXT Cycle 2
 ONCP GI GIGAVFFOXT Cycle 3
 ONCP GI GIGAVFFOXT Cycles 4+
 ONCP GI GIGAVTR

Versioning: Yes

Jira: CST-155033

Jira Ticket #	CST-203158, CST-203154, CST-203013, CST-203000, CST-202932, CST-202931, CST-202924, CST-202919, CST-202901, CST-202893, CST-155033
How-to questions?	http://cstcernerhelp.healthcarebc.ca/
Need further support?	CST Phone Support: 1-844-214-7444